Cytokinetics, Inc. Stock Nasdaq
Equities
US23282W1009
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
May. 09 | Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating | MT |
May. 08 | Cytokinetics Q1 Net Loss Narrows, Revenue Declines | MT |
Financials (USD)
Sales 2024 * | 8.85M | Sales 2025 * | 161M | Capitalization | 6.71B |
---|---|---|---|---|---|
Net income 2024 * | -440M | Net income 2025 * | -365M | EV / Sales 2024 * | 727 x |
Net cash position 2024 * | 276M | Net cash position 2025 * | 530M | EV / Sales 2025 * | 38.3 x |
P/E ratio 2024 * |
-14.8
x | P/E ratio 2025 * |
-19.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.42% |
Latest transcript on Cytokinetics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 60 | 98-06-30 |
Kari Loeser
CMP | Compliance Officer | - | 21-10-31 |
Stuart Kupfer
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy Wysenski
BRD | Director/Board Member | 66 | 20-11-19 |
Edward Kaye
BRD | Director/Board Member | 74 | 16-05-19 |
Santo Costa
BRD | Director/Board Member | 78 | 10-09-30 |
1st Jan change | Capi. | |
---|---|---|
+2.97% | 108B | |
+10.21% | 104B | |
+1.57% | 22.33B | |
-12.77% | 22.19B | |
-7.05% | 18.69B | |
-37.64% | 17.74B | |
-6.50% | 17.64B | |
+6.00% | 14.05B | |
+37.20% | 12.51B |